Severe coagulopathy in Jehovah's witness

Panchal, H.I.; Ramwell, J.

doi:10.1111/j.1365-2044.1989.tb11115.x

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The medium MW HES Pentastarch (MW 200 kDa) behaves similarly (82, 85), although it would appear that LMW HES and the more easily degradable forms of medium MW HES are not associated with this phenomenon (86). avWS presumably accounts for at least some of the clinically important, and even fatal, bleeding which has been reported after infusion of HES (81, 87, 88). Intracranial bleeding has been most commonly noted following the use of HES in management of intracranial vasospasm after subarachnoid hemorrhage (82) and neurosurgery (89).…”

Section: Drug‐induced Hemorrhagementioning

confidence: 99%

RAREACQUIREDBLEEDINGDISORDERS

Watson¹,

Chee²,

Greaves³

2001

Rev Clin Exp Hematol

View full text Add to dashboard Cite

Accurate diagnosis of the cause of bleeding is a prerequisite for determination of the optimal therapeutic response. Clinicians are generally aware of the more prevalent hemorrhagic syndromes but some rare acquired conditions are also of importance. In many of these, inhibitors of coagulation factors or of platelet adhesion/aggregation cause bleeding. These inhibitors are generally, but not always, immunoglobulins. In this review, the less common inhibitors of coagulation and hemostasis, as well as some important but rare nutritional, iatrogenic and disease associated hemorrhagic disorders, are described.

show abstract

Section: Drug‐induced Hemorrhagementioning

confidence: 99%

RAREACQUIREDBLEEDINGDISORDERS

Watson¹,

Chee²,

Greaves³

2001

Rev Clin Exp Hematol

View full text Add to dashboard Cite

show abstract

Hydroxyethyl Starch

Warren

Durieux

1997

Anesthesia & Analgesia

View full text Add to dashboard Cite

Effects of different plasma substitutes on blood coagulation: A comparative review

Jonge

Levi

2001

Critical Care Medicine

282

161

View full text Add to dashboard Cite

Dextran, gelatin, and hydroxyethyl starch (HES) all can induce a specific decrease of von Willebrand factor and factor VIII:c. Blood coagulation is most impaired by dextran and high molecular weight HES, both associated with increased postoperative blood loss. The effects of HES on blood coagulation have been shown to depend on its molecular weight and rate of elimination. Detrimental effects have been shown for high molecular weight HES. Medium molecular weight (MMW)-HES with a high degree of substitution (HES 200/0.62) and MMW-HES with high C2/C6 hydroxyethylation ratio (HES 200/0.5/13) are slowly degradable and have been shown to impair blood coagulation after repeated administration. Rapidly degradable HES 200/0.5/6 and gelatin-based plasma expanders appear not to impair hemostasis. However, based on the reviewed literature, all artificial colloids could potentially induce increased bleeding tendency after infusion of very large volumes and especially when given to patients with even mild forms of von Willebrand disease. In those circumstances, crystalloid solutions or alternatives such as plasma or albumin, although associated with other serious complications, could be considered.

show abstract

Severe coagulopathy in Jehovah's witness

Cited by 4 publications

References 1 publication

RAREACQUIREDBLEEDINGDISORDERS

RAREACQUIREDBLEEDINGDISORDERS

Hydroxyethyl Starch

Effects of different plasma substitutes on blood coagulation: A comparative review

Contact Info

Product

Resources

About